Skip to content

Large-scale household TB screening shows feasibility in PopART trial

Comfort Phiri presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016

Almost-certain case of PrEP failure due to drug resistance reported at CROI 2016

Early antiretroviral therapy reduces the risk of infection-related cancers

Early antiretroviral therapy reduces the risk of infection-related cancers

HIV in the brain: new tools and treatment to keep your mind beautiful

HIV in the brain: new tools and treatment to keep your mind beautiful

Removing clinic barriers to rapid initiation of ART in Uganda enables 70% to start on the same day

Gideon Amanyire presenting at CROI 2016. Image credit: www.croiwebcasts.org

Dolutegravir safe and highly effective in older children

Dolutegravir safe and highly effective in older children

Long-acting PrEP injection tolerable and acceptable for male volunteers, but dose adjustment needed

Martin Markowitz presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

Tenofovir alafenamide PrEP protects monkeys from infection, but rectal and vaginal levels in humans may be too low

Gerardo Garcia Lerma presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com

TAF/emtricitabine maintains viral suppression as well as TDF regimens with less bone and kidney toxicity

Joel Gallant presenting at CROI 2016. Photo by Liz Highleyman, hivandhepatitis.com